ISTOCK, MARK GILLOW
Selected stories from The Scientist’s reading list:
- Leaked World Health Organization documents obtained by ScienceInsider provide a more detailed picture of the financial and logistical issues surrounding Ebola vaccine development, as well as an estimate of when necessary stockpiles of the immunizations currently in development could be ready for testing and shipment. GlaxoSmithKline, one of the firms developing an Ebola vaccine, estimates “it will have 24,000 doses of its vaccine ready by January for . . . efficacy trials,” Science reported. Meanwhile, The New York Times reported that, in 2005, Canadian scientists published promising results for a candidate Ebola vaccine, noting it could be ready for testing and eventual licensing by 2011. “That vaccine,” the NYT noted, “sat on a shelf. Only now is it undergoing the most basic safety tests in humans—with nearly 5,000 people dead from Ebola and an epidemic raging out...
Interested in reading more?
The Scientist ARCHIVES
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!